Research Study on the Addition of Ixazomib to Standard Chemotherapy in Treatment of Mantle Cell Lymphoma

IRB/UVA Tracking #
20629
Principal Investigator
Craig A Portell
Contact
Erica Stallard
Contact Email
Contact Phone
342.243.2649
Official Trial Title
PrE0404
A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
Study Description

The University of Virginia Cancer Center seeks participants 18 years old or above to participate in a study that looks at whether the addition of a new drug – ixazomib – to standard treatment of ibrutinib chemotherapy is effective in treating people who have relapsed (come back) or refractory (progressed on treatment) mantle cell lymphoma.
Participation on this study may last up to 18 months.

Compensation

N/A